Gulin Oz, PhD

Professor, Department of Radiology

Gulin Oz

Contact Info

ozxxx001@umn.edu

Office Phone 612-626-2001

PhD, Biochemistry, University of Minnesota

BS, Physics and Chemistry, Bosphorus University, Istanbul, Turkey

Summary

Dr. Gülin Öz is a Professor in the Department of Radiology, Center for Magnetic Resonance Research (CMRR). Following BS degrees in Physics and Chemistry and a PhD in Biochemistry, she continued with postdoctoral training at the CMRR where she later joined the faculty. She uses high field, multi-nuclear magnetic resonance spectroscopy (MRS) to explore neurochemical and metabolic alterations in diseases that affect the brain and spearheaded utilization of neurochemical profiles to assess cerebral changes in patients with neurological diseases and their response to treatment. She focuses on applications of advanced MRS methods in neurodegenerative diseases and diabetes. She further leads efforts to facilitate the use and standardization of robust MRS methodology in the clinical setting.

Professional Associations

International Society for Magnetic Resonance in Medicine

American Diabetes Association

Society for Neuroscience

Research

Research Summary/Interests

  • To develop high and ultrahigh field MRS methodology for human and rodent applications.
  • To establish in vivo 1H MRS biomarkers of neurodegeneration, in parallel studies with patients and transgenic mouse models, with particular emphasis on movement disorders such as spinocerebellar ataxias and Parkinson’s disease. Such biomarkers are expected to facilitate early disease detection and treatment monitoring in pre-clinical and clinical trials.
  • To determine the effects of diabetes and the hypoglycemic consequences of intensive insulin therapy on brain glucose and glycogen metabolism and to elucidate pathogenic mechanisms of impaired awareness of hypoglycemia using MRS.

Publications

  • Deelchand DK, Kantarci K, Öz G. (2017) Improved localization, spectral quality and repeatability with advanced MRS methodology in the clinical setting, Magn Reson Med, DOI: 10.1002/mrm.26788.
  • Öz G, DiNuzzo M, Kumar A, Moheet A, Khowaja A, Kubisiak K, Eberly LE, Seaquist ER (2017) Cerebral Glycogen in Humans following Acute and Recurrent Hypoglycemia: Implications on a Role in Hypoglycemia Unawareness, J Cereb Blood Flow Metab, 37(8):2883-2893.
  • Terpstra M, Cheong I, Lyu T, Deelchand DK, Emir UE, Bednarík P, Eberly LE, Öz G (2016) Test-retest reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and 7T, Magn Reson Med, 76:1083–91.
  • Deelchand DK, Adanyeguh IM, Emir UE, Nguyen TM, Valabregue R, Henry PG, Mochel F, Öz G (2015) Two-site reproducibility of cerebellar and brainstem neurochemical profiles with short-echo, single voxel MRS at 3T, Magn Reson Med, 73: 1718-25.
  • Öz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, Bolan PJ, Brindle KM, Cudalbu C, Dincer A, Dydak U, Emir UE, Frahm J, González RG, Gruber S, Gruetter R, Gupta RK, Heerschap A, Henning A, Hetherington HP, Howe FA, Hüppi PS, Hurd RE, Kantarci K, Klomp DWJ, Kreis R, Kruiskamp MJ, Leach MO, Lin AP, Luijten PR, Marjanska M, Maudsley AA, Meyerhoff DJ, Mountford CE, Nelson SJ, Pamir MN, Pan JW, Peet AC, Poptani H, Posse S, Pouwels PJW, Ratai EM, Ross BD, Scheenen TWJ, Schuster C, Smith ICP, Soher BJ, Tkác I, Vigneron DB, Kauppinen RA. The MRS Consensus Group. (2014) Clinical Proton MR Spectroscopy in Central Nervous System Disorders, Radiology, 270(3):658-79.
  • Emir UE, Auerbach EJ, Van De Moortele PF, Marjanska M, Ugurbil K, Terpstra M, Tkác I, Öz G (2012) Regional neurochemical profiles in the human brain measured by 1H MRS at 7 tesla using local B1 shimming, NMR Biomed, 25: 152–160.
  • Öz G, Tkác I (2011) Short-echo, single-shot, full-intensity 1H MRS for neurochemical profiling at 4T: Validation in the cerebellum and brainstem, Magn Reson Med, 65(4):901-10.
  • Öz G, Nelson CD, Koski DM, Henry PG, Marjanska M, Deelchand DK, Shanley R, Eberly LE, Orr HT, Clark HB (2010) Noninvasive Detection of Pre-symptomatic and Progressive Neurodegeneration in a Mouse Model of Spinocerebellar Ataxia type 1, J Neurosci, 30:3831-3838.
  • Öz G, Hutter D, Tkác I, Clark HB, Gross MD, Jiang H, Eberly LE, Bushara KO, Gomez CM (2010) Neurochemical Alterations in Spinocerebellar Ataxia Type 1 and their Correlations with Clinical Status, Mov Disord, 25:1253–1261. 
  • Öz G, Kumar A, Rao JP, Kodl CT, Chow L, Eberly LE, Seaquist ER (2009) Human Brain Glycogen Metabolism during and following Hypoglycemia, Diabetes, 58(9):1978-85.
  • Tkác I, Öz G, Adriany G, Ugurbil K, Gruetter R (2009) In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: Metabolite quantification at 4T vs. 7T, Magn Reson Med, 62:868–879.
  • Öz G, Seaquist ER, Kumar A, Criego A, Benedict LE, Rao JP, Henry PG, van de Moortele PF, Gruetter R (2007) Human Brain Glycogen Content and Metabolism: Implications on its Role in Brain Energy Metabolism, Am J Physiol Endocrinol Metab, 292(3): E946-51.